Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 1
1(25.0%)
4Total
N/A(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04352803Phase 1Not Yet Recruiting

Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease

Role: lead

NCT03078686Not ApplicableUnknown

Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata

Role: lead

NCT03090672Not ApplicableUnknown

Cellular & Biocellular Regenerative Therapy in Musculoskeletal Pain, Dysfunction,Degenerative or Inflammatory Disease

Role: collaborator

NCT03297177Not ApplicableUnknown

Autologous Stem/Stromal Cells in Neurological Disorders and Disease

Role: lead

All 4 trials loaded